Healthcare-focused growth equity firm Essex Woodlands has named Cecilia Gonzalo to the post of managing director. Prior to joining Essex Woodlands, Gonzalo was a managing director for Warburg Pincus, where she focused exclusively on healthcare investments.
Essex Woodlands, a leading healthcare growth equity firm with a global investment practice, has announced the addition of Ms. Cecilia Gonzalo as Managing Director to their healthcare investment team. Ms. Gonzalo has 15 years of experience in healthcare investing and international finance and a successful investment track record across a broad range of pharmaceutical and health care services companies.
Prior to joining Essex Woodlands, Ms. Gonzalo was a Managing Director for Warburg Pincus LLC, where she focused exclusively on healthcare investments. Ms. Gonzalo led R&D and commercial due diligence, recruited senior management teams and completed diverse transaction structures, financings and exits, including most recently the sale of healthcare services company LaVie Care Centers and the financing of specialty pharmaceuticals company Inspire Pharmaceuticals. Ms. Gonzalo also collaborated with the global Warburg Pincus healthcare team to complete the $4.4B leveraged buyout of global eye health company, Bausch + Lomb and worked with the management team following the buyout on several licensing deals and add-on acquisitions, most recently the $500M acquisition of publicly traded US ophthalmic pharma company, ISTA Pharmaceuticals. She served on the Board of Directors of a number of Warburg Pincus healthcare portfolio companies, including Allos Therapeutics, Eurand N.V., Ganic Pharmaceuticals, LaVie Care Centers, Prestwick Pharmaceuticals, Rib-X Pharmaceuticals and Talon Therapeutics. She is also a Board member of the Saint Joseph’s University International Business Advisory Board.
Ms. Gonzalo is fluent in Spanish, Portuguese and French, and prior to joining Warburg Pincus, worked at Goldman Sachs in the firm’s Principal Investment Area and Investment Banking Division in the Latin America Group. Ms. Gonzalo was closely involved with advising Latin American clients on corporate finance and M&A transactions in a broad range of industries.
Steve Wiggins, the Managing Director who heads the New York office, commented, “Cecilia brings valuable international healthcare investing experience to this position, and will play a key role in broadening our investment practice to identify attractive investments in growth equity healthcare companies in the US and abroad. She will also create substantial value through her experience navigating complex organizational structures and managing key stakeholder and company relationships externally and internally.”
Ms. Gonzalo said of her appointment: “I am thrilled to be joining the team at Essex Woodlands, which has evolved into a leading global growth equity investor dedicated to healthcare. With over 28 years investing in healthcare, Essex Woodlands is very well-positioned to continue to create value for all stakeholders in the dynamic healthcare marketplace by partnering with world-class management teams and accelerating the growth of innovative businesses. I look forward to contributing to the growth of this firm’s investment practice, both in the US and overseas, particularly in Latin America.”
Ms. Gonzalo received her undergraduate degree in Biochemical Sciences from Harvard College, where she was a recipient of the Harvard College Scholarship Award and Elizabeth Cary Agassiz Merit Award, and her Master in Business Administration degree from Harvard Business School. Ms. Gonzalo will be based in the Essex Woodlands New York office, and will begin on April 2nd, 2013.
About Essex Woodlands — With $2.5 billion under management, Essex Woodlands is one of the largest and oldest growth equity and venture capital firms pursuing investments in pharmaceuticals, biotechnology, medical devices, health care services, and health information technology. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of over 150 healthcare companies ranging across all sectors, stages and geography. The team is comprised of 20 senior investment professionals with offices in Palo Alto, Houston, New York, London and Shanghai.